Amatuximab

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN) . Mesothelin is a glycosylphosphatidyl inositol (GPI) -anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium[1][2].

Product Specifications

CAS Number

[931402-35-6]

Product Name Alternative

MORab-009

UNSPSC

12352203

Target

Mesothelin

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/amatuximab.html

Purity

99.90

Solubility

H2O

Smiles

[Amatuximab]

Molecular Weight

(144.363 kDa)

References & Citations

[1]Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20 (23) :5927-5936. |[2]Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8.